Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Marimed (MRMD) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for Marimed (MRMD) over the last 15 years, with Q3 2025 value amounting to 3.92%.

  • Marimed's EBITDA Margin rose 6100.0% to 3.92% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.46%, marking a year-over-year decrease of 38100.0%. This contributed to the annual value of 1.84% for FY2024, which is 78400.0% down from last year.
  • As of Q3 2025, Marimed's EBITDA Margin stood at 3.92%, which was up 6100.0% from 2.88% recorded in Q2 2025.
  • In the past 5 years, Marimed's EBITDA Margin registered a high of 36.85% during Q2 2021, and its lowest value of 2.97% during Q4 2024.
  • Its 5-year average for EBITDA Margin is 10.68%, with a median of 8.48% in 2023.
  • The largest annual percentage gain for Marimed's EBITDA Margin in the last 5 years was 150700bps (2021), contrasted with its biggest fall of -356100bps (2021).
  • Marimed's EBITDA Margin (Quarter) stood at 3.88% in 2021, then soared by 122bps to 8.62% in 2022, then decreased by -28bps to 6.2% in 2023, then plummeted by -148bps to 2.97% in 2024, then skyrocketed by 232bps to 3.92% in 2025.
  • Its last three reported values are 3.92% in Q3 2025, 2.88% for Q2 2025, and 2.24% during Q1 2025.